Vericel's Chief Legal Officer Sean Flynn Purchases 15,000 Shares

Sean Flynn, the Chief Legal Officer of Vericel Corporation, acquired 15,000 shares of the company on June 26, 2026. The shares were purchased at an average price of $16.25, amounting to a total value of $243,750. This transaction was not part of a prearranged 10b5-1 trading plan.

Other Institutional Activity in Vericel Corporation

Several institutional investors have recently adjusted their holdings in Vericel Corporation. BlackRock, Inc. increased its stake by 58,269 shares, bringing its total to 7,765,344 shares valued at approximately $249.8 million, marking a 0.8% increase. State Street Corp decreased its holdings by 11,792 shares, now holding 3,152,130 shares worth about $101.4 million, a 0.4% decrease. Soleus Capital Management, L.P. significantly boosted its position by 1,785,079 shares, ending with 2,549,079 shares valued at $82.0 million, reflecting a 233.6% increase. Conestoga Capital Advisors, LLC added 208,750 shares, resulting in a total of 2,463,312 shares worth roughly $79.2 million, a 9.3% increase. Vanguard Capital Management LLC opened a new position with 2,230,756 shares valued at approximately $71.8 million.

Vericel Corporation Stock Up 8.6%

Shares of NasdaqGM:VCEL traded near $44.49 on Wednesday. Vericel Corporation, with a market cap of about $2.27 billion, has a P/E ratio of 103.5 and a forward P/E of 52.2. The stock has a 52-week low of $28.95 and a high of $46.62. Its 50-day moving average stands at $36.28, while the 200-day moving average is $35.73. The company maintains a current ratio of 5.18 and a quick ratio of 4.62, with a debt-to-equity ratio of 26.68.

Recent Earnings

Vericel Corporation reported revenue of $292.1 million, with a growth rate of 30.1%. The company's earnings per share (EPS) were $0.43, and it achieved a net margin of 7.3% and a return on equity (ROE) of 6.6%. The next earnings report is scheduled for July 30, 2026.

Insider Buying and Selling at Vericel Corporation

In addition to Sean Flynn's purchase, Jonathan Siegal, the Principal Accounting Officer, bought 2,500 shares at $29.82 on June 26, 2026. Jonathan Mark Hopper, Chief Medical Officer, also acquired 5,000 shares at the same price on the same day. These transactions were not part of any prearranged plans.

Analysts Set New Price Targets

On April 15, 2026, Truist Securities maintained its buy rating on Vericel with a price target of $42. HC Wainwright & Co. also maintained a buy rating with a target of $64 on February 27, 2026. The consensus among analysts is a buy rating, with an average target price of $55.43 based on seven analyst opinions.

About Vericel Corporation

Vericel Corporation is a biopharmaceutical company based in Burlington, Massachusetts. It focuses on developing and marketing cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company's key products include MACI, Epicel, and NexoBrid. Vericel was formerly known as Aastrom Biosciences and changed its name in 2014. It is led by CEO Mr. Dominick C. Colangelo and employs about 398 people.

Bottom Line

Vericel Corporation continues to attract insider interest, with Sean Flynn's recent purchase highlighting confidence in the company's future. The stock's current trading price and recent institutional activity suggest ongoing interest from investors. As always, the 13F filings and insider transactions are backward-looking and may not reflect current positions.